Clinical trial NCT02200887 - References

Parkinson Disease — Sleep Homeostasis in Parkinson's Disease

Citation(s)

•   Antonini A, Ursino G, Calandrella D, Bernardi L, Plebani M
  Continuous dopaminergic delivery in Parkinson's disease. J Neurol. 2010 Nov;257(Suppl 2):S305-8. doi: 10.1007/s00415-010-5714-1. Review.
•   Bassetti CL
  Nonmotor disturbances in Parkinson's disease. Neurodegener Dis. 2011;8(3):95-108. doi: 10.1159/000316613. Epub 2010 Dec 23. Review.
•   Bateman DE, Levett K, Marsden CD
  Sleep benefit in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):384-5.
•   Benninger DH, Michel J, Waldvogel D, Candia V, Poryazova R, van Hedel HJ, Bassetti CL
  REM sleep behavior disorder is not linked to postural instability and gait dysfunction in Parkinson. Mov Disord. 2010 Aug 15;25(11):1597-604. doi: 10.1002/mds.23121.
•   Berthet A, Bezard E
  Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S8-12. doi: 10.1016/S1353-8020(09)70827-2. Review.
•   Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B
  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010 Nov;9(11):1106-17. doi: 10.1016/S1474-4422(10)70218-0. Epub 2010 Sep 27. Review.
•   Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF
  REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010 Aug 10;75(6):494-9. doi: 10.1212/WNL.0b013e3181ec7fac. Epub 2010 Jul 28.
•   Currie LJ, Bennett JP Jr, Harrison MB, Trugman JM, Wooten GF
  Clinical correlates of sleep benefit in Parkinson's disease. Neurology. 1997 Apr;48(4):1115-7.
•   Devos D; French DUODOPA Study Group
  Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009 May 15;24(7):993-1000. doi: 10.1002/mds.22450.
•   Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J
  Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med. 2005 Jul;6(4):313-8.
•   Dodel RC, Berger K, Oertel WH
  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics. 2001;19(10):1013-38. Review.
•   Galati S, Stanzione P, D'Angelo V, Fedele E, Marzetti F, Sancesario G, Procopio T, Stefani A
  The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway. J Physiol. 2009 Sep 15;587(Pt 18):4405-23. doi: 10.1113/jphysiol.2009.172759. Epub 2009 Jul 21.
•   Huot P, Fox SH, Brotchie JM
  The serotonergic system in Parkinson's disease. Prog Neurobiol. 2011 Oct;95(2):163-212. doi: 10.1016/j.pneurobio.2011.08.004. Epub 2011 Aug 22. Review.
•   Jankovic J, Stacy M
  Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. Review.
•   Jenner P
  Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol. 2008 Dec;64 Suppl 2:S16-29. doi: 10.1002/ana.21489. Review.
•   Katzenschlager R, Lees AJ
  Treatment of Parkinson's disease: levodopa as the first choice. J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.
•   Langston JW, Ballard P
  Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci. 1984 Feb;11(1 Suppl):160-5.
•   Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R
  Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. J Neural Transm Suppl. 1999;56:173-83. Review.
•   Mercuri NB, Bernardi G
  The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci. 2005 Jul;26(7):341-4. Review.
•   Möller JC, Rethfeldt M, Körner Y, Stiasny-Kolster K, Cassel W, Meindorfner C, Rissling I, Krüger HP, Oertel WH
  Daytime sleep latency in medication-matched Parkinsonian patients with and without sudden onset of sleep. Mov Disord. 2005 Dec;20(12):1620-2.
•   Möller JC, Unger M, Stiasny-Kolster K, Kaussner Y, Penzel T, Oertel WH, Hemmeter U
  Continuous sleep EEG monitoring in PD patients with and without sleep attacks. Parkinsonism Relat Disord. 2009 Mar;15(3):238-41. doi: 10.1016/j.parkreldis.2008.05.009. Epub 2008 Jul 10.
•   Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M
  Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.
•   Nadjar A, Gerfen CR, Bezard E
  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009 Jan 12;87(1):1-9. doi: 10.1016/j.pneurobio.2008.09.013. Epub 2008 Sep 30. Review.
•   Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team
  Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004 Oct;61(10):1563-8.
•   Olanow CW, Obeso JA, Stocchi F
  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006 Aug;5(8):677-87. Review.
•   Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F
  Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging. 2010 Sep 7;5:229-38. Review.
•   Poewe W, Högl B
  Parkinson's disease and sleep. Curr Opin Neurol. 2000 Aug;13(4):423-6. Review.
•   Romigi A, Placidi F, Peppe A, Pierantozzi M, Izzi F, Brusa L, Galati S, Moschella V, Marciani MG, Mazzone P, Stanzione P, Stefani A
  Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease. Eur J Neurol. 2008 Jul;15(7):e64-5. doi: 10.1111/j.1468-1331.2008.02167.x. Epub 2008 May 15. Erratum in: Eur J Neurol. 2008 Jul;15(7):e57.
•   Rye DB, Jankovic J
  Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002 Feb 12;58(3):341-6. Review.
•   Stefani A, Galati S, Brusa L, Pierantozzi M, Peppe A, Stanzione P
  Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine. BMJ Case Rep. 2010 Nov 18;2010. pii: bcr0220102774. doi: 10.1136/bcr.02.2010.2774.
•   Stefani A, Galati S, Peppe A, Bassi A, Pierantozzi M, Hainsworth AH, Bernardi G, Orlacchio A, Stanzione P, Mazzone P
  Spontaneous sleep modulates the firing pattern of parkinsonian subthalamic nucleus. Exp Brain Res. 2006 Jan;168(1-2):277-80. Epub 2005 Nov 18.
•   Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ, Mayer G, Möller JC, Oertel WH, Knake S
  Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep. 2010 Jun;33(6):767-73.
•   Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR
  Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol. 2010 Dec;17(12):1428-36. doi: 10.1111/j.1468-1331.2010.03063.x.

Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease

Details for clinical trial NCT02200887